MultiPath Discovery

MultiPath Discovery

Antibody Discovery. Any Target. Any Format

A format-agnostic platform configured for your target biology and built for clinical success. FairJourney Bio designs each campaign backwards from your Target Product Profile — then executes it with the integrated depth of a full discovery-to-IND CRO.

Discuss Your Project 

Antibody Discovery. Any Target. Any Format

A format-agnostic platform configured for your target biology and built for clinical success. FairJourney Bio designs each campaign backwards from your Target Product Profile — then executes it with the integrated depth of a full discovery-to-IND CRO.

Discuss Your Project 

Antibody Discovery. Any Target. Any Format

A format-agnostic platform configured for your target biology and built for clinical success. FairJourney Bio designs each campaign backwards from your Target Product Profile — then executes it with the integrated depth of a full discovery-to-IND CRO.

Discuss Your Project 

>1,400

projects completed

>250

Global partners

>19

assets in clinical development

2

assets in Phase III

Start With the End in Mind

Most discovery platforms give you a workflow. MultiPath Discovery gives you a strategy. Before a single panning round begins, our scientific lead designs the optimal combination of diversity source, screening platform, and molecular format for your specific target and Target Product Profile.

The result: higher hit rates, better developability profiles, and a lead series that is ready for the next stage of your programme.

Explore the full discovery-to-IND offering

Solutions for Every Application

  • Bispecific and multispecific antibodies

  • Internalising mAbs for ADC programmes

  • pH-selective binders

  • Dual binders

  • TCR mimetics

  • CAR constructs

  • Fc isotype variants and engineered Fc mutants

  • Tool antibodies for target validation

  • VHH nanobodies and VHH-Fc fusions

  • Anti-idiotype antibodies and clinical assay tools

  • Biomarker detection and sandwich pairs

Solutions for Every Application

  • Bispecific and multispecific antibodies

  • Internalising mAbs for ADC programmes

  • pH-selective binders

  • Dual binders

  • TCR mimetics

  • CAR constructs

  • Fc isotype variants and engineered Fc mutants

  • Tool antibodies for target validation

  • VHH nanobodies and VHH-Fc fusions

  • Anti-idiotype antibodies and clinical assay tools

  • Biomarker detection and sandwich pairs

Solutions for Every Application

  • Bispecific and multispecific antibodies

  • Internalising mAbs for ADC programmes

  • pH-selective binders

  • Dual binders

  • TCR mimetics

  • CAR constructs

  • Fc isotype variants and engineered Fc mutants

  • Tool antibodies for target validation

  • VHH nanobodies and VHH-Fc fusions

  • Anti-idiotype antibodies and clinical assay tools

  • Biomarker detection and sandwich pairs

One CRO. All the Way to IND

MultiPath Discovery feeds directly into FairJourney Bio's integrated development capability. One project lead. One data thread. No handoffs, no gaps between stages.

Explore discovery-to-IND

Explore the full discovery-to-IND offering

A Modular Architecture for Every Target

The Platform

MultiPath Discovery is built around three independent axes — source of diversity, discovery platform, and final molecular format. For every project, our scientific leads select the combination that gives your programme the best probability of delivering a clinical candidate.

A Modular Architecture for Every Target

The Platform

MultiPath Discovery is built around three independent axes — source of diversity, discovery platform, and final molecular format. For every project, our scientific leads select the combination that gives your programme the best probability of delivering a clinical candidate.

A Modular Architecture for Every Target

The Platform

MultiPath Discovery is built around three independent axes — source of diversity, discovery platform, and final molecular format. For every project, our scientific leads select the combination that gives your programme the best probability of delivering a clinical candidate.

Axis 1 — Sources of Diversity

The starting diversity determines what is discoverable. MultiPath Discovery provides access to three distinct repertoire types, each optimised for a different scientific objective.

Naïve — Broadest coverage. Any target

Sourced from unimmunised human donors and llamas. Ideal for targets with low immunogenicity or close homology to self-antigens. Library diversity >10¹⁰ clones in ScFv, Fab, and VHH formats. κ and λ light chains. Common light chain available.

Semi-Synthetic — Engineered for developability

Human donor frameworks combined with computationally optimised synthetic CDR design. Developability is selected at the library level — before a single clone is characterised. Library diversity up to 10¹¹ clones. Proprietary Cosmic Library and SuperHuman 2.0.

Immune — Highest affinity. Maximum potency

Antigen-experienced repertoires from immunised animals or human patients. Library diversity 10⁶–10⁹ clones in ScFv, Fab, and IgG formats. Multiple species supported, including mice, rabbits, llamas, and human patients. Recovery by phage display and single B-cell.

NEW - fully human antibody transgenic mice - Abtherx ™ partnership - integrated with our B-Cell navigator platform.

Axis 1 — Sources of Diversity

The starting diversity determines what is discoverable. MultiPath Discovery provides access to three distinct repertoire types, each optimised for a different scientific objective.

Naïve — Broadest coverage. Any target

Sourced from unimmunised human donors and llamas. Ideal for targets with low immunogenicity or close homology to self-antigens. Library diversity >10¹⁰ clones in ScFv, Fab, and VHH formats. κ and λ light chains. Common light chain available.

Semi-Synthetic — Engineered for developability

Human donor frameworks combined with computationally optimised synthetic CDR design. Developability is selected at the library level — before a single clone is characterised. Library diversity up to 10¹¹ clones. Proprietary Cosmic Library and SuperHuman 2.0.

Immune — Highest affinity. Maximum potency

Antigen-experienced repertoires from immunised animals or human patients. Library diversity 10⁶–10⁹ clones in ScFv, Fab, and IgG formats. Multiple species supported, including mice, rabbits, llamas, and human patients. Recovery by phage display and single B-cell.

NEW - fully human antibody transgenic mice - Abtherx ™ partnership - integrated with our B-Cell navigator platform.

Axis 1 — Sources of Diversity

The starting diversity determines what is discoverable. MultiPath Discovery provides access to three distinct repertoire types, each optimised for a different scientific objective.

Naïve — Broadest coverage. Any target

Sourced from unimmunised human donors and llamas. Ideal for targets with low immunogenicity or close homology to self-antigens. Library diversity >10¹⁰ clones in ScFv, Fab, and VHH formats. κ and λ light chains. Common light chain available.

Semi-Synthetic — Engineered for developability

Human donor frameworks combined with computationally optimised synthetic CDR design. Developability is selected at the library level — before a single clone is characterised. Library diversity up to 10¹¹ clones. Proprietary Cosmic Library and SuperHuman 2.0.

Immune — Highest affinity. Maximum potency

Antigen-experienced repertoires from immunised animals or human patients. Library diversity 10⁶–10⁹ clones in ScFv, Fab, and IgG formats. Multiple species supported, including mice, rabbits, llamas, and human patients. Recovery by phage display and single B-cell.

NEW - fully human antibody transgenic mice - Abtherx ™ partnership - integrated with our B-Cell navigator platform.

Axis 2 — Discovery Platforms

Each diversity source can be screened using one or more of four orthogonal platforms — selected based on your target, format, and functional requirements. Full detail in the Discovery Platforms tab.


  • Phage Display — broadest library access, fastest timelines: 6–8 weeks

  • Mammalian Display — developability-linked, patent-protected: 8–10 weeks

  • Yeast Display — quantitative FACS multi-parameter selection: 8–10 weeks

  • Single B-Cell — natively paired VH-VL from human patients and mice: 8–10 weeks

Axis 2 — Discovery Platforms

Each diversity source can be screened using one or more of four orthogonal platforms — selected based on your target, format, and functional requirements. Full detail in the Discovery Platforms tab.


  • Phage Display — broadest library access, fastest timelines: 6–8 weeks

  • Mammalian Display — developability-linked, patent-protected: 8–10 weeks

  • Yeast Display — quantitative FACS multi-parameter selection: 8–10 weeks

  • Single B-Cell — natively paired VH-VL from human patients and mice: 8–10 weeks

Axis 2 — Discovery Platforms

Each diversity source can be screened using one or more of four orthogonal platforms — selected based on your target, format, and functional requirements. Full detail in the Discovery Platforms tab.


  • Phage Display — broadest library access, fastest timelines: 6–8 weeks

  • Mammalian Display — developability-linked, patent-protected: 8–10 weeks

  • Yeast Display — quantitative FACS multi-parameter selection: 8–10 weeks

  • Single B-Cell — natively paired VH-VL from human patients and mice: 8–10 weeks

Axis 3 — Final Format

Campaigns are configured to deliver leads in your required final format from day one. No reformatting. No re-characterisation.


  • IgG1, IgG2, IgG4 and engineered Fc variants

  • Fab, scFv

  • VHH nanobody and VHH-Fc fusion

  • Biparatopic VHH

  • Bispecific and multispecific formats

  • Common light chain for bispecific assembly

Axis 3 — Final Format

Campaigns are configured to deliver leads in your required final format from day one. No reformatting. No re-characterisation.


  • IgG1, IgG2, IgG4 and engineered Fc variants

  • Fab, scFv

  • VHH nanobody and VHH-Fc fusion

  • Biparatopic VHH

  • Bispecific and multispecific formats

  • Common light chain for bispecific assembly

Axis 3 — Final Format

Campaigns are configured to deliver leads in your required final format from day one. No reformatting. No re-characterisation.


  • IgG1, IgG2, IgG4 and engineered Fc variants

  • Fab, scFv

  • VHH nanobody and VHH-Fc fusion

  • Biparatopic VHH

  • Bispecific and multispecific formats

  • Common light chain for bispecific assembly

Libraries Built for the Clinic. Exclusive to FairJourney Bio

Proprietary Libraries   

Most antibody libraries are designed to produce hits. FairJourney Bio's proprietary libraries are designed to produce drugs. Developability is hardwired into the diversity — so the clones you advance are already fit for clinical development.

Access is exclusive. No licensing. No competitor access. Lineage gatekeeping protects your programme's IP throughout.

Libraries Built for the Clinic. Exclusive to FairJourney Bio

Proprietary Libraries   

Most antibody libraries are designed to produce hits. FairJourney Bio's proprietary libraries are designed to produce drugs. Developability is hardwired into the diversity — so the clones you advance are already fit for clinical development.

Access is exclusive. No licensing. No competitor access. Lineage gatekeeping protects your programme's IP throughout.

Libraries Built for the Clinic. Exclusive to FairJourney Bio

Proprietary Libraries   

Most antibody libraries are designed to produce hits. FairJourney Bio's proprietary libraries are designed to produce drugs. Developability is hardwired into the diversity — so the clones you advance are already fit for clinical development.

Access is exclusive. No licensing. No competitor access. Lineage gatekeeping protects your programme's IP throughout.

Cosmic Library

FairJourney Bio's flagship library. 100 billion fully human scFv clones. Used in more than 70% of all Tumbler campaigns since its 2022 launch.

Architecture


  • Memory layer: natural CDRs from BCR-seq data across 100 NGS-filtered donors — memory and naïve B cells

  • Oligo layer: liability-free synthetic CDRs optimised for Tumbler CDR shuffling compatibility

  • 25 drug-worthy frameworks: 5 VH × 5 VK, 100% germline, including 16 novel frameworks

  • 100bn scFvs — virtually no clonal redundancy, improved CDR-H3 and L3 diversity

What this means for your programme


  • Verified developability from the first round of selection

  • Optimised for low immunogenicity — fully human, germline frameworks

  • Exclusive to FairJourney Bio — no licensing, lineage gatekeeping, zero competitor access

In practice: SIRPα

Target with 80% homology to cynomolgus SIRPα and 87% homology to SIRPβ. Using the Cosmic Library: 22 of 25 reformatted IgGs functional at low-nM affinity. 82% showed Tm >68°C; 86% showed Tagg >65°C. 21 distinct epitope bins identified.

Cosmic Library

FairJourney Bio's flagship library. 100 billion fully human scFv clones. Used in more than 70% of all Tumbler campaigns since its 2022 launch.

Architecture


  • Memory layer: natural CDRs from BCR-seq data across 100 NGS-filtered donors — memory and naïve B cells

  • Oligo layer: liability-free synthetic CDRs optimised for Tumbler CDR shuffling compatibility

  • 25 drug-worthy frameworks: 5 VH × 5 VK, 100% germline, including 16 novel frameworks

  • 100bn scFvs — virtually no clonal redundancy, improved CDR-H3 and L3 diversity

What this means for your programme


  • Verified developability from the first round of selection

  • Optimised for low immunogenicity — fully human, germline frameworks

  • Exclusive to FairJourney Bio — no licensing, lineage gatekeeping, zero competitor access

In practice: SIRPα

Target with 80% homology to cynomolgus SIRPα and 87% homology to SIRPβ. Using the Cosmic Library: 22 of 25 reformatted IgGs functional at low-nM affinity. 82% showed Tm >68°C; 86% showed Tagg >65°C. 21 distinct epitope bins identified.

Cosmic Library

FairJourney Bio's flagship library. 100 billion fully human scFv clones. Used in more than 70% of all Tumbler campaigns since its 2022 launch.

Architecture


  • Memory layer: natural CDRs from BCR-seq data across 100 NGS-filtered donors — memory and naïve B cells

  • Oligo layer: liability-free synthetic CDRs optimised for Tumbler CDR shuffling compatibility

  • 25 drug-worthy frameworks: 5 VH × 5 VK, 100% germline, including 16 novel frameworks

  • 100bn scFvs — virtually no clonal redundancy, improved CDR-H3 and L3 diversity

What this means for your programme


  • Verified developability from the first round of selection

  • Optimised for low immunogenicity — fully human, germline frameworks

  • Exclusive to FairJourney Bio — no licensing, lineage gatekeeping, zero competitor access

In practice: SIRPα

Target with 80% homology to cynomolgus SIRPα and 87% homology to SIRPβ. Using the Cosmic Library: 22 of 25 reformatted IgGs functional at low-nM affinity. 82% showed Tm >68°C; 86% showed Tagg >65°C. 21 distinct epitope bins identified.

SuperHuman 2.0

76 billion fully human scFv clones. An NGS-informed library where developability is engineered into every clone and genuine sequence diversity is proven, not assumed.

  • CDR-H3 and L3 from naïve repertoire — other CDRs from memory B-cell compartment

  • ~100 donor immune repertoires combined

  • Highest-frequency VH paratope = 0.03% of library — truly unique sequence space

  • CDRH3 sequences average 9.7 amino acids apart

  • Thermostability, aggregation resistance, and low immunogenicity built in

  • 5 SuperHuman-derived antibodies currently in clinical trials

SuperHuman 2.0

76 billion fully human scFv clones. An NGS-informed library where developability is engineered into every clone and genuine sequence diversity is proven, not assumed.

  • CDR-H3 and L3 from naïve repertoire — other CDRs from memory B-cell compartment

  • ~100 donor immune repertoires combined

  • Highest-frequency VH paratope = 0.03% of library — truly unique sequence space

  • CDRH3 sequences average 9.7 amino acids apart

  • Thermostability, aggregation resistance, and low immunogenicity built in

  • 5 SuperHuman-derived antibodies currently in clinical trials

SuperHuman 2.0

76 billion fully human scFv clones. An NGS-informed library where developability is engineered into every clone and genuine sequence diversity is proven, not assumed.

  • CDR-H3 and L3 from naïve repertoire — other CDRs from memory B-cell compartment

  • ~100 donor immune repertoires combined

  • Highest-frequency VH paratope = 0.03% of library — truly unique sequence space

  • CDRH3 sequences average 9.7 amino acids apart

  • Thermostability, aggregation resistance, and low immunogenicity built in

  • 5 SuperHuman-derived antibodies currently in clinical trials

Explorer Platform

Fully human ScFv, Fab, common LC and humanised VHH* libraries with selected, developability-optimised frameworks. Rapid affinity maturation by CDR cassette shuffling. The preferred tool for fast-cycle maturation without sacrificing biophysical quality.

*Early access Q1 2027

Explorer Platform

Fully human ScFv, Fab, common LC and humanised VHH* libraries with selected, developability-optimised frameworks. Rapid affinity maturation by CDR cassette shuffling. The preferred tool for fast-cycle maturation without sacrificing biophysical quality.

*Early access Q1 2027

Explorer Platform

Fully human ScFv, Fab, common LC and humanised VHH* libraries with selected, developability-optimised frameworks. Rapid affinity maturation by CDR cassette shuffling. The preferred tool for fast-cycle maturation without sacrificing biophysical quality.

*Early access Q1 2027

Full Framework Libraries

The broadest natural framework coverage available. Framework and CDR repertoires from more than 100 human donors. Separate κ and λ light chain libraries. Up to 50 billion clones per library in ScFv and Fab phage display formats.

Full Framework Libraries

The broadest natural framework coverage available. Framework and CDR repertoires from more than 100 human donors. Separate κ and λ light chain libraries. Up to 50 billion clones per library in ScFv and Fab phage display formats.

Full Framework Libraries

The broadest natural framework coverage available. Framework and CDR repertoires from more than 100 human donors. Separate κ and λ light chain libraries. Up to 50 billion clones per library in ScFv and Fab phage display formats.

Hit Rates Across Target Classes

  • Immune checkpoint (soluble): 93%

  • Virus-associated antigen: 77%

  • Tumour-associated antigen: 74%

  • Receptor tyrosine kinase: 58–79% (across library formats)

  • Transmembrane single-pass Type I: 77%

Hit Rates Across Target Classes

  • Immune checkpoint (soluble): 93%

  • Virus-associated antigen: 77%

  • Tumour-associated antigen: 74%

  • Receptor tyrosine kinase: 58–79% (across library formats)

  • Transmembrane single-pass Type I: 77%

Hit Rates Across Target Classes

  • Immune checkpoint (soluble): 93%

  • Virus-associated antigen: 77%

  • Tumour-associated antigen: 74%

  • Receptor tyrosine kinase: 58–79% (across library formats)

  • Transmembrane single-pass Type I: 77%

Discovery Platforms   

The Right Platform for Every Discovery Challenge

Platform selection is a scientific decision. FairJourney Bio operates all four major antibody screening technologies and designs multi-platform strategies when the biology demands it.

Phage Display

The broadest format coverage and the fastest timelines in FairJourney Bio's discovery engine.

  • Formats: ScFv, Fab, VHH, VHH-Fc, biparatopic-VHH

  • Panning: solid-phase, in-solution, cell-based, pH-selective

  • Library access: Cosmic, SuperHuman 2.0, Explorer, Full Framework

  • Affinity engineering: Explorer and Tumbler CDR shuffling integrated

  • Timeline: 6–8 weeks

Best for: naïve and semi-synthetic library campaigns, broad epitope mapping, speed-critical programmes.

Phage Display

The broadest format coverage and the fastest timelines in FairJourney Bio's discovery engine.

  • Formats: ScFv, Fab, VHH, VHH-Fc, biparatopic-VHH

  • Panning: solid-phase, in-solution, cell-based, pH-selective

  • Library access: Cosmic, SuperHuman 2.0, Explorer, Full Framework

  • Affinity engineering: Explorer and Tumbler CDR shuffling integrated

  • Timeline: 6–8 weeks

Best for: naïve and semi-synthetic library campaigns, broad epitope mapping, speed-critical programmes.

Mammalian Display

Antibodies displayed in their final therapeutic format on mammalian cells. Display level correlates directly with CMC properties — developability is selected for, not screened for retrospectively. Patent-protected worldwide.

  • Formats: ScFv, Fab, VHH, VHH-Fc, biparatopic-VHH

  • Library: 10⁶–10⁷ variants

  • Multi-parametric: affinity, developability, and function screened simultaneously

  • Integrates with phage display: diversity to developability in one workflow

  • Timeline: 8–10 weeks

Best for: bispecifics, multispecifics, and any format where biophysical behaviour in a mammalian system must be confirmed alongside affinity.

Yeast Display

FACS-based quantitative screening enabling simultaneous multi-condition selection — pH, affinity, dual binding, and cross-reactivity in one workflow.

  • Formats: ScFv, Fab, VHH, VHH-Fc, biparatopic-VHH

  • Multi-parametric: affinity, dual-binding, pH-differential, cross-reactivity

  • Phage display integration: diversity to multi-parameter selection in one workflow

  • Timeline: 8–10 weeks

Best for: pH-selective binders, dual binders, any programme requiring simultaneous selection across multiple functional conditions.

Yeast Display

FACS-based quantitative screening enabling simultaneous multi-condition selection — pH, affinity, dual binding, and cross-reactivity in one workflow.

  • Formats: ScFv, Fab, VHH, VHH-Fc, biparatopic-VHH

  • Multi-parametric: affinity, dual-binding, pH-differential, cross-reactivity

  • Phage display integration: diversity to multi-parameter selection in one workflow

  • Timeline: 8–10 weeks

Best for: pH-selective binders, dual binders, any programme requiring simultaneous selection across multiple functional conditions.

Single B-Cell Screening

Natively paired VH-VL recovery from B cells of immunised animals or human patients — preserving the biological context of antibody maturation in every sequence recovered.

  • Natively paired VH-VL — natural architecture preserved

  • 10⁶–10⁷ B-cells per run

  • Species: human patients and mice

  • B-cell populations: surface Ig and secretory Ig

  • Timeline: 8–10 weeks from terminal bleed

Best for: immune campaigns requiring natively paired sequences, human patient diversity, or programmes where antigen-experienced affinity maturation must be preserved.

Single B-Cell Screening

Natively paired VH-VL recovery from B cells of immunised animals or human patients — preserving the biological context of antibody maturation in every sequence recovered.

  • Natively paired VH-VL — natural architecture preserved

  • 10⁶–10⁷ B-cells per run

  • Species: human patients and mice

  • B-cell populations: surface Ig and secretory Ig

  • Timeline: 8–10 weeks from terminal bleed

Best for: immune campaigns requiring natively paired sequences, human patient diversity, or programmes where antigen-experienced affinity maturation must be preserved.

Combining Platforms

The most powerful discovery campaigns use more than one platform. A naïve phage screen maps accessible epitope space. An immune campaign delivers affinity. Mammalian display confirms developability before lead commitment. FairJourney Bio's scientific project leads design these multi-platform strategies and execute them with full data continuity throughout.

Combining Platforms

The most powerful discovery campaigns use more than one platform. A naïve phage screen maps accessible epitope space. An immune campaign delivers affinity. Mammalian display confirms developability before lead commitment. FairJourney Bio's scientific project leads design these multi-platform strategies and execute them with full data continuity throughout.

Applications

Every Modality. Validated at Scale

Over 1,400 completed projects across the full spectrum of therapeutic antibody formats. Here is how MultiPath Discovery is applied to the most common — and most complex — modalities.

Bispecific & Multispecific Antibodies

Common light chain library formats simplify downstream bispecific assembly. Mammalian display confirms the full molecule's developability in its therapeutic format. FairJourney Bio's engineering team refines individual arms post-characterisation when needed.

Recommended path: Phage Display (building blocks) + Mammalian Display (full molecule).

Internalising mAbs for ADC Programmes

Cell-based panning strategies enrich for internalising clones directly at the library screening stage. Functional internalisation validation available through FunctionInsight Assays.

Internalising mAbs for ADC Programmes

Cell-based panning strategies enrich for internalising clones directly at the library screening stage. Functional internalisation validation available through FunctionInsight Assays.

pH-Selective Binders

Yeast and mammalian display platforms both support pH-differential panning as a primary selection parameter. pH-switching behaviour is identified at library stage — not engineered in after the fact.

pH-Selective Binders

Yeast and mammalian display platforms both support pH-differential panning as a primary selection parameter. pH-switching behaviour is identified at library stage — not engineered in after the fact.

Dual Binders

FACS-based yeast display enables quantitative selection for simultaneous engagement of two epitopes — on the same antigen or two distinct targets — in a single workflow.

Dual Binders

FACS-based yeast display enables quantitative selection for simultaneous engagement of two epitopes — on the same antigen or two distinct targets — in a single workflow.

TCR Mimetics

Cell-based counter-selection protocols using phage and yeast display drive allele-specific selectivity against the relevant peptide-MHC complex and HLA background.

TCR Mimetics

Cell-based counter-selection protocols using phage and yeast display drive allele-specific selectivity against the relevant peptide-MHC complex and HLA background.

CAR Constructs & CAR-T Building Blocks

scFv and VHH hits delivered in formats directly compatible with CAR construct assembly. Functional CAR-T cytotoxicity validation available through FunctionInsight Assays.

CAR Constructs & CAR-T Building Blocks

scFv and VHH hits delivered in formats directly compatible with CAR construct assembly. Functional CAR-T cytotoxicity validation available through FunctionInsight Assays.

Fc Engineering & Isotype Variants

Hits delivered in the required Fc background from the outset. Full range of Fc modifications — effector function, FcRn interaction, half-life engineering — supported through DeepDesign Engineering.

Fc Engineering & Isotype Variants

Hits delivered in the required Fc background from the outset. Full range of Fc modifications — effector function, FcRn interaction, half-life engineering — supported through DeepDesign Engineering.

Tool Antibodies & Target Validation Reagents

Naïve library phage display for fast, high-quality tool antibody generation. More than a thousand tool antibody campaigns completed across diverse target classes.

Tool Antibodies & Target Validation Reagents

Naïve library phage display for fast, high-quality tool antibody generation. More than a thousand tool antibody campaigns completed across diverse target classes.

Anti-Idiotype Antibodies & Clinical Assay Tools

Anti-idiotype antibodies for PK and immunogenicity assays, sandwich pairs for bioanalytical platforms, and clinical-stage assay reagent packages — with integrated FunctionInsight Assays development.

Anti-Idiotype Antibodies & Clinical Assay Tools

Anti-idiotype antibodies for PK and immunogenicity assays, sandwich pairs for bioanalytical platforms, and clinical-stage assay reagent packages — with integrated FunctionInsight Assays development.

Don't see your application? Tell us about your target.

Explore the full discovery-to-IND offering

Transparent from Day One

Process & Deliverables   

Every MultiPath Discovery project runs with full partner visibility. A single scientific project lead is accountable from kick-off to hit delivery — the same person who designs the strategy, reviews the data, and makes the experimental decisions.

Transparent from Day One

Process & Deliverables   

Every MultiPath Discovery project runs with full partner visibility. A single scientific project lead is accountable from kick-off to hit delivery — the same person who designs the strategy, reviews the data, and makes the experimental decisions.

Access is exclusive. No licensing. No competitor access. Lineage gatekeeping protects your programme's IP throughout.

Transparent from Day One

Process & Deliverables   

Every MultiPath Discovery project runs with full partner visibility. A single scientific project lead is accountable from kick-off to hit delivery — the same person who designs the strategy, reviews the data, and makes the experimental decisions.

Workflow

01

Scientific Alignment & Strategy Design

Target biology and Target Product Profile reviewed together. A bespoke discovery strategy is documented and shared with the partner before any work begins.

02

Antigen Preparation & Library Setup

FairJourney Bio produces antigen if not provided by the partner. Library preparation and immunisation proceed in parallel, minimising programme start time.

03

Discovery Screening

Panning rounds executed with intermediate data shared at each milestone. Strategy adjustments are made collaboratively — our scientific lead drives the experimental direction.

04

Hit Confirmation & Characterisation

Hits expressed, purified, and confirmed by ELISA and/or SPR. Sequence diversity and initial selectivity data generated and shared.

05

Data Transfer & Programme Transition

Full data package delivered. Where the programme continues within FairJourney Bio, the same project lead manages the transition — same team, same data, zero re-learning curve.

What You Receive

  • Sequence-confirmed antibody hits in your required final format

  • Binding data: affinity, selectivity, and cross-reactivity characterisation

  • Sequence diversity analysis: V-gene usage, CDR lengths, clonal family distribution

  • Intermediate report and Certificate of Analysis at each workpackage end — raw and processed data

  • Clone overview document (Excel): per-clone screening data and V-gene sequences for all hits

  • Final project report: experimental design, decision log, hit series summary

  • Full data security — your programme data is never shared across projects

How We Work

  • Science-driven — our scientific project lead calls the experimental shots

  • Collaborative — regular sync meetings, shared decision-making with your team

  • Transparent — real-time dedicated data sharing space, no black box

  • Secure — highest data security standards, fully independent programmes

Fullspectrum Characterization

fullspectrum-characterization

AnyFormat Manufacturing

anyformat-manufacturing

DeepDesign Engineering

deepdesign-engineering

FunctionInsight Assays

functioninsight-assays

B-Cell Navigator

b-cell-navigator

Solutions

solutions

Platforms & Technologies

platforms-technologies

Why FJBio

why-fjbio

Events & Resources

events-resources

Company

company

About

about

Antibody Discovery

antibody-discovery

Protein Production

protein-production

AtomicLevel Cryo-EM

atomic-level-cryo-em

Biologistics

biologistics

Leadership

leadership

Careers

careers

News & Insights

news-insights

Case Studies

case-studies

Fact Sheets

fact-sheets

CellCraft Solutions

cellcraft-solutions

Cryo-EM

cryo-em

Display Platforms

display-platforms

Events

events

Library Diversity

library-diversity

MultiPath Discovery

multipath-discovery

Publications & Posters

publications-posters

Resources

resources

Screening | Analytics | Data Engines

screening-analytics-data-engines

Single B-Cell Screening

single-b-cell-screening

The Antibody Series Conference

the-antibody-series-conference

Tumbler™

tumbler

Webinars

webinars

White papers

whitepapers

Contact Us

contact-us

Download